Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.

Saxena V, Terrault N.

Curr Opin Organ Transplant. 2012 Jun;17(3):216-24. doi: 10.1097/MOT.0b013e3283534d64. Review.

PMID:
22476221
2.

Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors.

Londoño MC, Crespo G, Forns X.

Curr Opin Organ Transplant. 2013 Jun;18(3):271-8. doi: 10.1097/MOT.0b013e3283614aca. Review.

PMID:
23665543
3.

Future perspectives: towards interferon-free regimens for HCV.

Gane E.

Antivir Ther. 2012;17(6 Pt B):1201-10. doi: 10.3851/IMP2431. Review.

PMID:
23186654
4.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
5.

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).

Italian Association for the Study of the Liver (AISF)., Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board:..

Dig Liver Dis. 2014 Jan;46(1):18-24. doi: 10.1016/j.dld.2013.08.243. Review.

6.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Review.

PMID:
22951253
7.

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.

Gambarin-Gelwan M, Jacobson IM.

Curr Gastroenterol Rep. 2012 Feb;14(1):47-54. doi: 10.1007/s11894-011-0237-1. Review.

PMID:
22161022
8.

Management of post transplant hepatitis C in the direct antiviral agents era.

Coilly A, Roche B, Duclos-Vallée JC, Samuel D.

Hepatol Int. 2015 Apr;9(2):192-201. doi: 10.1007/s12072-015-9621-5. Review.

PMID:
25820797
9.

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.

Esteban R, Buti M.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):445-53. doi: 10.1016/j.bpg.2012.09.001. Review.

PMID:
23199503
10.

A new era in the treatment of chronic hepatitis C infection.

Jothimani D, Chandy GM, Conjeevaram H.

Indian J Gastroenterol. 2013 Mar;32(2):71-9. doi: 10.1007/s12664-012-0254-5. Review.

PMID:
23054947
11.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver..

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

12.

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.

Leroy V, Serfaty L, Bourlière M, Bronowicki JP, Delasalle P, Pariente A, Pol S, Zoulim F, Pageaux GP; French Association for the Study of the Liver..

Liver Int. 2012 Nov;32(10):1477-92. doi: 10.1111/j.1478-3231.2012.02856.x. Review.

PMID:
22891751
13.

Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.

Trembling PM, Tanwar S, Dusheiko GM.

Expert Rev Anti Infect Ther. 2012 Mar;10(3):269-79. doi: 10.1586/eri.12.8. Review.

PMID:
22397560
14.

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.

Lam JT, Jacob S.

Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500. Review.

PMID:
23230035
15.

Anemia management in patients with chronic viral hepatitis C.

Hynicka LM, Heil EL.

Ann Pharmacother. 2013 Feb;47(2):228-36. doi: 10.1345/aph.1R513. Review.

PMID:
23386076
16.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Review.

PMID:
22156853
17.

Treatment of chronic hepatitis C virus infection after liver transplantation.

Agarwal K, Barnabas A.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S349-54. doi: 10.1016/j.dld.2013.07.014. Review.

PMID:
24091115
18.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.

PMID:
22404758
19.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
20.

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].

Albillos A, Luis Calleja J, Molina E, Planas R, Romero-Gómez M, Turnes J, Hernández-Guerra M.

Gastroenterol Hepatol. 2014 Jul;37 Suppl 1:13-22. doi: 10.1016/S0210-5705(15)30003-0. Review. Spanish.

PMID:
25907434
Items per page

Supplemental Content

Support Center